Medigen Vaccine Biologics Corp. (MVC) entered a global commercial license agreement with National Institutes of Health (NIH) on May 5th. Within the agreement, NIH grants MVC the rights to obtain the original biomaterials of recombinant spike protein, the antibodies for analysis, the technology platform and the patents related to the platform and the vaccine candidate. From this agreement, MVC has the right to develop, and commercialize worldwide.
The recombinant spike protein has been well researched for the development of vaccines for SARS, MERS and other coronaviruses. At the beginning of the COVID-19 outbreak, NIH designed this recombinant spike protein based on the previous platform of recombinant spike protein. MVC has conducted preclinical immunogenicity studies in early March and has completed preliminary testing and evaluation.
MVC will continue the development of existing research achievements and discuss with National Regulatory Authorities the pathway of Emergency Use Authorizations (EUA) to accelerate the launch of COVID-19 vaccines.
【About Medigen Vaccine Biologics Corp., MVC】
MVC is a cell-based biopharmaceutical company focusing on the development and production of vaccines and biologics. MVC's business partners include US NIH, US CDC, WHO/UCAB, Taiwan CDC, and Taiwan National Health Research Institute. MVC's pipeline includes enterovirus A71 vaccine, dengue vaccine, influenza quadrivalent vaccine which all entered late clinical stage.
【About National Institutes of Health (NIH)】
The National Institutes of Health is the world's top research institution in the field of biomedicine and its annual budget of R & D is nearly US $ 40 billion. NIH has developed the platform of coronavirus vaccines for many years and has successfully selected COVID-19 vaccine candidate. MVC has collaboratd with NIH for vaccine development on Dengue vaccines since 2015.